2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Artificial Intelligence (AI), Computer Vision, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Microbiome, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

5668 Measurable residual disease results and impact on efficacy with dose-modified fixed-duration ibrutinib-venetoclax in previously untreated chronic lymphocytic leukemia: Extended follow-up from the prospective phase 2 TAILOR study

Paolo Ghia, MD, PhD, Jan Novak, PhD2, Jana Mihalyova, MD3, Michael Doubek, MD4, Mitul Gandhi, MD5, Agnieszka Giza, MD, PhD6, Zsolt Lazar, MD7, Laszlo Rejto, PhD, MD8, Luca Laurenti Sr, MD9, Alessandro Sanna, MD10, CelesteAnn Bremer, MD11, Paolo Sportoletti, MD, PhD12, Jacqueline Barrientos, MD13, Francesc Bosch, MD14, Lucrecia Yanez San Segundo15, Jan A. Burger, MD, PhD16, Mark Hoffman, BSEE, MSEE17, Brian Koffman, MDCM18, Gabriel Krigsfeld, PhD19, Christopher Abbazio, PharmD20, Erin Franceschini, MS21, Magdalena Uhart22, Irina Usankova23, Flavia Pinho24, John Loffredo, PhD25, Zacharias Anastasiou26, Huiling Pei27, Mohamed Morsy28, Qing Li, MD, PhD29, Barbara Pinto30, Sowmya Srikanthan31, Boo Messahel, MB chB, MD32, Lori Parisi33, Mark Wildgust, PhD34, Jeff Sharman, MD35
1 IRCCS Ospedale San Raffaele, Milan, Italy, Università Vita-Salute San Raffaele, Milan, Italy
2 University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Prague, Czech Republic
3 University Hospital Ostrava, Ostrava, Czech Republic
4 University Hospital Brno, Brno, Czech Republic
5 Virginia Cancer Specialists, Fairfax, Virginia, United States
6 Jagiellonian University Medical College, Krakow, Poland
7 Petz Aladár County Teaching Hospital, Gyor, Hungary
8 Szabolcs-Szatmár-Bereg County Teaching Hospital, Nyíregyháza, Hungary
9 Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
10 Azienda Ospedaliero Universitaria Careggi, Florence, Italy
11 Virginia Oncology Associates, Virginia Beach, Virginia, United States
12 Santa Maria della Misericordia Hospital, Perugia, Italy
13 Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
14 Vall D’Hebron University Hospital, Barcelona, Spain
15 University Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain
16 MD Anderson Cancer Center, Houston, Texas, United States
17 University of California, San Diego, California, United States
18 CLL Society Inc., Nashville, Tennessee, United States
19 AbbVie, North Chicago, Illinois, United States
20 AbbVie, North Chicago, Illinois, United States
21 AbbVie, North Chicago, Illinois, United States
22 AbbVie, North Chicago, Illinois, United States
23 Johnson & Johnson, Allschwil, Switzerland
24 Johnson & Johnson, San Diego, California, United States
25 Johnson & Johnson, Spring House, Pennsylvania, United States
26 Johnson & Johnson, Athens, Greece
27 Johnson & Johnson, Titusville, New Jersey, United States
28 Johnson & Johnson, Dubai, United Arab Emirates
29 Johnson & Johnson, Raritan, New Jersey, United States
30 Johnson & Johnson, Porto Salvo, Portugal
31 Johnson & Johnson, Somerset, New Jersey, United States
32 Johnson & Johnson, Raritan, New Jersey, United States
33 Johnson & Johnson, Raritan, New Jersey, United States
34 Johnson & Johnson, Raritan, New Jersey, United States
35 Willamette Valley Cancer Institute, Eugene, Oregon, United States

Introduction: Fixed-duration (FD) ibrutinib-venetoclax (Ibr+Ven) has demonstrated deep responses and high rates of undetectable measurable residual disease (uMRD) in previously untreated chronic lymphocytic leukemia (CLL). At 3 months (mo) post end of treatment (EOT+3), peripheral blood (PB) uMRD rates were 55% in GLOW, 57% in CAPTIVATE, and 47% in CLL17 (Kater. NEJM Evid. 2022;1:EVIDoa2200006; Tam. Blood. 2022;139:3278-89; Al-Sawaf. N Engl J Med. 2026;394:1084-96). The phase 2 TAILOR study was designed to prospectively evaluate reactive (per prescribing information [PI] guidance) and proactive Ibr dose-reduction approaches during FD Ibr+Ven treatment. While dose reduction may improve treatment tolerability, its impact on depth of remission, including uMRD achievement, and subsequent clinical outcomes have not been fully characterized.

Here we present extended follow-up (FU) from the TAILOR FD Ibr+Ven arm, reporting PB MRD results, efficacy outcomes, and safety following dose-modification strategies.

Methods: Patients (pts) with untreated CLL/small lymphocytic lymphoma from the FD Ibr+Ven arm were randomized 1:1 into either reactive (1A) or proactive (1B) dose-reduction cohorts. Pts in cohort 1A received a 3-cycle lead-in with 420 mg daily (QD) Ibr followed by 12 cycles of FD Ibr+Ven with 420 mg QD Ibr; pts received dose reductions per PI guidance. Pts in cohort 1B received 3 cycles of 420 mg QD Ibr followed by 12 cycles of FD Ibr+Ven with a proactive dose reduction to 280 mg QD Ibr. Ven step-up and dosing were administered per label. The primary end point was overall response rate (ORR). Secondary end points included progression-free survival (PFS) and overall survival (OS). Safety results are descriptive. TAILOR was not powered for inter-cohort comparisons. MRD was assessed in PB only via next-generation sequencing during screening and at 3 and 12 mo post EOT in all pts. uMRD was defined as < 1 CLL cell per 10,000 leukocytes (10-4). uMRD rates (EOT+3) were reported among evaluable pts with ≥ 1 post-baseline MRD assessment. Results from EOT+12 will be reported in the future.

Results: In cohort 1A (n = 86): median age was 63 years (y), 4.7% had a CIRS score > 6, 16.3% had del(17p)/TP53 aberration, and 36.0% had an unmutated IGHV (uIGHV) status. Median time on study was 20.4 mo. In all pts, ORR was 94.2%; 18-mo PFS and OS were 81.5% and 98.8%, respectively. Of 60 pts with evaluable MRD, the PB uMRD rate at EOT+3 was 65.0%. In pts with uMRD/detectable MRD (dMRD), 33.3%/47.6% had a uIGHV status. ORR was 100%/100%, 18-mo PFS was not estimable (NE)/100%, and 18-mo OS was 100%/100%. In all pts, Ibr-related adverse events (AEs) were reported in 78.8%, Ibr-related serious AEs in 7.1%, and grade ≥ 3 AEs in 50.6%. AEs leading to Ibr discontinuation, dose reduction, and interruption were reported in 7.1%, 18.8%, and 49.4%, respectively. One AE-related death was reported.

In cohort 1B (n = 85): median age was 63 y, 8.2% had a CIRS score > 6, 9.4% had del(17p)/TP53 aberration, and 41.2% had a uIGHV status. Median time on study was 20.5 mo. In all pts, ORR was 90.6%; 18-mo PFS and OS were NE and 98.8%, respectively. Of 62 pts with evaluable MRD, the PB uMRD rate at EOT+3 was 43.5%. In pts with uMRD/dMRD, 40.7%/40.0% had a uIGHV status. ORR was 100%/94.3%, 18-mo PFS was NE/NE, and 18-mo OS was 100%/100%. In all pts, Ibr-related AEs were reported in 71.8%, Ibr-related serious AEs in 4.7%, and grade ≥ 3 AEs in 51.8%. AEs leading to Ibr discontinuation, dose reduction, and interruption were reported in 12.9%, 14.1%, and 40.0%, respectively. One AE-related death was reported.

Conclusions: With extended FU in the prospective phase 2 TAILOR FD Ibr+Ven arm, reactive and proactive Ibr dose-reduction strategies were associated with high ORR and sustained PFS and OS outcomes, with generally similar safety profiles between cohorts. Although TAILOR was not powered for inter-cohort comparisons and MRD results are limited to evaluable pts with PB assessment, the numerically higher PB uMRD rate at EOT+3 observed with label-aligned 420 mg Ibr initiation followed by reactive dose reductions supports the approved dosing approach for FD Ibr+Ven, with dose modifications applied as needed for tolerability. These findings demonstrate that the label-aligned Ibr+Ven dose achieves deep early responses that are comparable to those reported in historical clinical trials.

Paolo Ghia, MD, PhD: AstraZeneca - Honoraria; Nurix - Honoraria; MSD - Honoraria; BeOne Medicines - Honoraria; BMS - Honoraria; Eli Lilly - Honoraria; AbbVie - Honoraria; Roche - Honoraria; Johnson & Johnson - Honoraria; AstraZeneca - Research Funding; AbbVie - Research Funding; Eli Lilly - Research Funding; BeOne Medicines - Research Funding; Johnson & Johnson - Research Funding; Roche - Research Funding; MSD - Research Funding; Nurix - Research Funding; BeOne Medicines - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Curis, Inc. - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); MSD - Consultancy (Includes expert testimony); Nurix - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony)